drugset / Trial / NCT01119157

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines

NCT01119157

RandomizedParallel-groupSingle-blindPrevention

Summary

This is a randomized, single-blinded, Phase IV, monocentric study in healthy adults aged \> 18 and \< 60 years to evaluate the cellular and humoral immunogenicity as well as the reactogenicity of intramuscular, inactivated, trivalent influenza vaccines, including aluminium adjuvanted whole virus vaccine, split vaccine and subunit vaccine.

Timeline

Start
2008-11
Primary completion
2009-03
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 15 ug Intramuscular

Indications

No indication recorded.